One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Veracyte logo
Veracyte VCYT
$ 43.12 1.16%
report update icon

Quarterly report 2026-Q2
added 07-31-2026

Veracyte Financial Statements 2025-2010 | VCYT

Annual Financial Statements Veracyte

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Market Cap

3.04 B 2.96 B 1.71 B 1.68 B 2.8 B 3.11 B 1.23 B 654 M 220 M 214 M 168 M 175 M 61.6 M - - -

Shares

78.6 M 76.5 M 72.6 M 71.5 M 67.9 M 54.9 M 46.1 M 37 M 33.9 M 28.8 M 25.9 M 21.6 M 4.16 M - - -

Historical Prices

38.7 38.7 23.5 23.5 41.2 48.9 27.9 12.6 6.53 7.74 7.2 9.66 14.5 - - -

Net Income

66.4 M 24.1 M -74.4 M -36.6 M -75.6 M - -12.6 M -23 M -31 M -31.4 M -33.7 M -29.4 M -25.6 M -18.6 M -14.4 M -

Revenue

517 M 446 M 361 M 297 M 220 M 117 M 120 M 92 M 72 M 65.1 M 49.5 M 38.2 M 21.9 M 11.6 M 2.64 M -

Cost of Revenue

- - - - - - 36.1 M 33.1 M 28.2 M 25.5 M 21.5 M 16.6 M 12.6 M 7.58 M 2.92 M -

Gross Profit

363 M 298 M 230 M 176 M - 76 M 83.8 M 58.9 M 43.8 M 39.6 M 28 M 21.6 M 9.28 M 4.04 M -280 K -

Operating Income

57.8 M 16.1 M -85.8 M -41.1 M -81.9 M -35.4 M -15.1 M -22.2 M -26.5 M -28.8 M -33.5 M -29 M -23.2 M -18.9 M -15.3 M -

Interest Expense

10.4 M 9.6 M 9.18 M 4.65 M 254 K 229 K 677 K 1.96 M 4.94 M 2.76 M 378 K 439 K 233 K 280 K 819 K -

EBITDA

79.2 M 39.6 M -58.6 M -15.2 M -62.3 M -27.4 M -12.3 M -19.5 M -23.4 M -27.7 M -32.7 M -27.8 M -22.2 M -18.2 M -14.7 M -

Operating Expenses

- - - - - 153 M 99 M 81.2 M 70.3 M 68.4 M 61.5 M 50.6 M 32.4 M 23 M 15 M -

General and Administrative Expenses

111 M 111 M 86.2 M 73.2 M 101 M 35.2 M 27.6 M 22.3 M 30.3 M 32 M 29.7 M 24.2 M 12.1 M 7.92 M 5.37 M -

All numbers in USD currency

Quarterly Income Statement Veracyte

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

80 M 79.5 M 78.7 M 78.4 M 78 M 77.8 M 77 M 76.5 M 74.8 M 73.3 M 72.8 M 72.5 M 72.2 M 72 M 71.7 M 71.5 M 71.2 M 71.1 M 69.7 M 67.3 M 63.3 M 58 M 54.9 M 50.2 M 49.8 M 49.1 M 48.6 M 45.6 M 41.2 M 40.7 M 38.6 M 34.3 M 34.3 M 35.1 M 33.9 M 33.9 M 33.8 M 31.7 M 27.9 M 27.9 M 27.8 M 27.7 M 27.6 M 26 M 22.5 M 22.5 M 21.6 M 21.2 M 21.1 M 13.9 M 956 K 862 K 763 K 665 K 659 K 653 K 624 K - - - -

Net Income

25.5 M 28.7 M 19.1 M -980 K 7.05 M - 15.2 M 5.73 M -1.86 M - -29.6 M -8.4 M -8.09 M - -8.72 M -9.53 M -14.5 M - -14.1 M -9.04 M -41.9 M -8.04 M -4.12 M -11 M -11.7 M -7.46 M -730 K -2.49 M -1.92 M -3.1 M -4.47 M -6.25 M -9.18 M -8.44 M -7.05 M -7.3 M -8.22 M -4.4 M -5.64 M -11.2 M -10.1 M -8.01 M -8.94 M -9.14 M -7.61 M -8.14 M -7.9 M -6.66 M -6.67 M -5.89 M -6.3 M -6.49 M -6.9 M -4.84 M -4.94 M -4.63 M -4.25 M - - - -

Revenue

150 M 139 M 132 M 130 M 114 M - 116 M 114 M 96.8 M - 90.1 M 90.3 M 82.4 M - 75.6 M 72.9 M 67.8 M - 60.4 M 55.1 M 36.7 M 34.5 M 31.1 M 20.7 M 31.1 M 29.7 M 31 M 30.1 M 29.5 M 25.8 M 23.5 M 22.8 M 20 M 19.6 M 17.5 M 18.4 M 16.4 M 18.3 M 18.6 M 14.7 M 13.6 M 14 M 12.3 M 11.9 M 11.2 M 12.2 M 9.84 M 8.68 M 7.48 M 6.84 M 5.59 M 5.07 M 4.38 M 4.46 M 3.22 M 2.48 M 1.47 M - - - -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - 9.11 M 8.78 M 8.51 M - 8.26 M 8.25 M 7.87 M - 7.17 M 6.96 M 6.3 M - 6.37 M 6.3 M 6.28 M - 5.62 M 5.14 M 4.57 M - 4.17 M 3.97 M 3.61 M - 3.13 M 3.23 M 2.77 M - 1.98 M - - - - - -

Gross Profit

109 M 101 M 91.3 M 89.8 M 79.5 M - 79 M 77.9 M 62.5 M - 57.7 M 55.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

23 M 22.6 M 22.9 M -5.27 M 2.9 M - 12 M 4.61 M -4.66 M - -31.7 M -8.05 M -10.5 M - -9.68 M -10.7 M -15.2 M - -16.7 M -7.47 M -45.4 M - -4.07 M -11.1 M -12.2 M - -1.76 M -3.1 M -2.07 M - -4.3 M -5.92 M -8.96 M - -6.37 M -6.61 M -7.52 M - -4.89 M -10.5 M -9.75 M - -8.89 M -9.07 M -7.55 M - -7.81 M -6.56 M -6.58 M - -6.1 M -5.42 M -5.89 M - -4.94 M - - - - - -

Interest Expense

3.54 M 7.33 M -4.06 M 6.52 M 4.52 M - 4.83 M 2.76 M 2.75 M - 1.97 M -226 K 2.41 M - 805 K 1.09 M 784 K - 1.2 M 63 K 53 K - 55 K 65 K 55 K - 58 K 235 K 303 K - 498 K 481 K 448 K - 815 K 808 K 800 K - 799 K 785 K 367 K - 92 K 90 K 89 K - 114 K 113 K 111 K - 126 K 5 K -1 M - 1 K - - - - - -

EBITDA

33.2 M 28.1 M 26.2 M -1.97 M 8.27 M - 15.8 M 8.41 M 934 K - -26.4 M -2.75 M -3.83 M - -4.47 M -5.34 M -8.69 M - -3.49 M -3.75 M -42.9 M - 1.85 M -7.12 M -10.2 M - 1.07 M -1.23 M -1.12 M - -1.35 M -3.95 M -7.98 M - -3.53 M -4.76 M -6.62 M - -2.28 M -8.79 M -8.99 M - -7.25 M -8.08 M -7.2 M - -6.98 M -6.02 M -6.31 M - -5.38 M -4.99 M -5.7 M - -4.41 M - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 21.2 M 21 M 18.8 M - 17.6 M 15.2 M 14.1 M - 11.7 M 10.5 M 10.3 M - 8.16 M - - - - - -

General and Administrative Expenses

27.4 M 23.7 M 27.3 M 32.3 M 33.8 M - 25.7 M 31.7 M 26.2 M - 16.3 M 25 M 21.1 M - 17.6 M 19.8 M 20.9 M - 20.7 M 15.5 M 46.3 M - 8.55 M 7.96 M 7.81 M - 6.62 M 6.92 M 6.9 M - 5.74 M 5.93 M 5.64 M - 5.52 M 6.19 M 6.02 M - 5.76 M 6.07 M 6.23 M - 5.73 M 5.54 M 5.8 M - 5.72 M 3.93 M 3.98 M - 3.24 M 2.74 M 2.79 M - 2.1 M - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Veracyte VCYT
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Veracyte plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 9.52 5.01 % $ 752 M usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Histogen Histogen
HSTO
- 31.6 % $ 2.12 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 24.02 0.39 % $ 3.64 B usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 17.61 2.63 % $ 3.04 B usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.38 0.79 % $ 278 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Precision BioSciences Precision BioSciences
DTIL
$ 5.77 2.32 % $ 74 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.35 7.49 % $ 209 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 31.32 4.36 % $ 1.82 B usaUSA
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
$ 11.1 2.59 % $ 237 K usaUSA
Exelixis Exelixis
EXEL
$ 62.23 0.06 % $ 16.9 B usaUSA
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
$ 2.99 4.32 % $ 219 K usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.17 1.53 % $ 275 K usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 0.67 0.14 % $ 172 M usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
$ 49.51 1.0 % $ 201 B britainBritain
GT Biopharma GT Biopharma
GTBP
$ 7.03 18.52 % $ 38.8 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 0.36 4.01 % $ 60 M usaUSA
Johnson & Johnson Johnson & Johnson
JNJ
$ 255.56 0.86 % $ 615 B usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 8.18 19.02 % $ 551 B britainBritain
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 28.82 10.19 % $ 3.67 B usaUSA
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 0.7 0.62 % $ 42 M usaUSA
Kura Oncology Kura Oncology
KURA
$ 9.08 0.94 % $ 796 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
- -3.69 % $ 12.4 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 34.99 3.77 % $ 147 M usaUSA
Alector Alector
ALEC
$ 1.84 6.02 % $ 190 M usaUSA
ObsEva SA ObsEva SA
OBSV
- -15.52 % $ 10.5 M schweizSchweiz
Kronos Bio Kronos Bio
KRON
- 1.49 % $ 50.8 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
PhaseBio Pharmaceuticals PhaseBio Pharmaceuticals
PHAS
- 7.4 % $ 6.29 M usaUSA
Provention Bio Provention Bio
PRVB
- - $ 2.37 B usaUSA
Poseida Therapeutics Poseida Therapeutics
PSTX
- - $ 857 M usaUSA
PolarityTE PolarityTE
PTE
- -0.82 % $ 1.78 M usaUSA
Reata Pharmaceuticals Reata Pharmaceuticals
RETA
- - $ 6.29 B usaUSA
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.06 6.0 % $ 56.9 M usaUSA
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 0.98 0.09 % $ 226 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
Satsuma Pharmaceuticals Satsuma Pharmaceuticals
STSA
- -0.9 % $ 36.5 M usaUSA
SpringWorks Therapeutics SpringWorks Therapeutics
SWTX
- - $ 3.48 B usaUSA
Trevena Trevena
TRVN
- -46.58 % $ 31.8 M usaUSA
Oncorus Oncorus
ONCR
- -8.54 % $ 3.19 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA